Connect your AI

GeneDx Holdings WGS Settlement Liabilities (Current)

Settlement Liabilities (Current) at other companies

Twist Bioscience CorporationTWST

——

Other financials

Income statement

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

Market cap$1.89B-24.3%

Enterprise value$1.89B-22.8%

P/S4.3×-3.3×

Profitability

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:SettlementLiabilitiesCurrent.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's settlement liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is GeneDx Holdings's settlement liabilities (current)?: GeneDx Holdings (WGS) reported settlement liabilities (current) of $4.75M in Q1 2026.